Do Black and Latina women report different GLP-1 side effects?

Key takeaways

Dr. Linda's take

I get this question a lot, and I want to answer it the way I would want it answered for me: honestly, including the parts we do not know well yet.

Here is the short version. The everyday side effects of these medications are mostly about the gut, and that broad picture looks similar no matter who you are. What is genuinely under-studied is whether Black and Latina women experience those effects at meaningfully different rates, because the trials that built the evidence base did not enroll enough women of color to answer that question with confidence. So when someone tells you the side effects are exactly the same, or dramatically different, by race, be a little skeptical. The truthful answer is "broadly similar, but not studied as deeply as it deserves to be."

I would rather give you that honest answer than a tidy one. Knowing where the evidence is solid and where it is thin is exactly what lets you have a real conversation with your own clinician instead of a hopeful one. This connects to a bigger set of questions about whether these medications work as well for Black and Latina women once someone is actually taking them.

What side effects are most common for everyone?

Start with the shared picture, because it is the most solid part.

For semaglutide, the drug label lists the most common adverse reactions, reported in at least 5 percent of patients, as nausea, diarrhea, vomiting, constipation, and abdominal pain, along with headache, fatigue, and dizziness. In the STEP 1 trial of semaglutide for weight management, nausea and diarrhea were the most common adverse events, and they were typically transient and mild-to-moderate in severity and subsided with time. A similar story appeared with the other main medication in this class. In the SURMOUNT-1 trial of tirzepatide, the most common adverse events were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation.

The through-line is that the headline side effects are digestive, tend to be mild to moderate, and often ease as the body adjusts. That is the baseline every patient is working from, and nothing in the data suggests that baseline flips upside down for one group versus another.

Were Black and Latina women well represented in the trials?

This is where the honesty comes in, and it is the crux of the whole question.

A 2024 systematic review of 27 randomized trials of GLP-1 medicines for obesity, with more than 21,000 participants, found that White participants made up about 79 percent of those enrolled, while Black participants made up about 9 percent and Hispanic participants about 22 percent. In that same review, the proportion of non-White individuals in these trials was significantly under-represented compared with the general population of the United States.

You can see the same pattern inside the flagship semaglutide studies. In a post hoc analysis of the STEP 1 and STEP 3 trials, participants reported their race as White in about 75 percent of cases, Black in about 9 percent, and Asian in about 11 percent, and about 14 percent reported Hispanic or Latino ethnicity.

Why does this matter for side effects specifically? Because when a subgroup is small, it is harder to detect a real difference in how often something like nausea happens, even if one exists. The absence of a clear signal is not the same as proof of no difference. That is the representation gap, and it is worth naming, which is a theme that also runs through whether Black and Latina women were included in these weight-loss trials.

Is there evidence the side effect profile differs by race?

Here is the reassuring part, held gently because the samples were modest.

Researchers did go back and look. In a post hoc analysis of the STEP 1 and STEP 3 trials, the safety of semaglutide was consistent across racial and ethnic subgroups, and all subgroups showed good tolerability. That same analysis found no significant interactions between the treatment effect and race or ethnicity.

Read plainly, that means the researchers did not find a race-specific side-effect profile hiding in the data they had. What it does not mean is that the question is fully settled, because the number of Black and Latina participants was still limited. So the fair summary is this: the evidence we have points to a broadly similar profile, and there is no good data showing that Black and Latina women should expect a fundamentally different set of side effects. What is missing is large, deliberately diverse research designed to answer the question with real statistical power.

That gap sits alongside two other realities for women of color: a documented difference in who actually gets prescribed these medications, and a higher baseline risk of obesity and diabetes in the first place. If you are trying to figure out whether treatment is even a fit for your situation, our eligibility quiz is one place to begin.

Frequently asked questions

Do Black and Latina women get different GLP-1 side effects than other women?

The most honest answer is that the side-effect profile looks broadly similar across groups, but it has not been studied as deeply in Black and Latina women as it should be. Where researchers have looked, tolerability was consistent across racial and ethnic subgroups. There is no reliable evidence pointing to a fundamentally different set of side effects by race.

What are the most common GLP-1 side effects?

They are mostly digestive. For semaglutide, the drug label lists the most common adverse reactions, reported in at least 5 percent of patients, as nausea, diarrhea, vomiting, constipation, and abdominal pain, along with headache, fatigue, and dizziness. These effects are often mild to moderate and tend to ease over time.

Why is the race-specific data so limited?

Because the trials that built the evidence base enrolled mostly White participants. A 2024 systematic review of 27 randomized trials of GLP-1 medicines for obesity, with more than 21,000 participants, found that White participants made up about 79 percent of those enrolled, while Black participants made up about 9 percent and Hispanic participants about 22 percent. Smaller subgroups make race-specific differences harder to detect.

Does a smaller subgroup mean the medication is less safe for women of color?

No. A small subgroup means less statistical certainty, not more danger. In a post hoc analysis of the STEP 1 and STEP 3 trials, the safety of semaglutide was consistent across racial and ethnic subgroups, and all subgroups showed good tolerability. The takeaway is that the question deserves bigger, more diverse studies, not that a warning sign has been found.

What can I do with this information?

Use it to ask specific questions. You can ask your clinician what side effects to watch for, how they are typically managed, and what the plan is if they show up. Knowing that the general profile is digestive and usually temporary, and that the race-specific data is still thin, lets you walk in informed rather than guessing.

References

1. Novo Nordisk (2026). WEGOVY (semaglutide) injection, for subcutaneous use - prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b (Accessed 2026-07-22).
2. The New England journal of medicine (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. PubMed PMID 33567185. https://pubmed.ncbi.nlm.nih.gov/33567185/ (Accessed 2026-07-22).
3. The New England journal of medicine (2022). Tirzepatide Once Weekly for the Treatment of Obesity. PubMed PMID 35658024. https://pubmed.ncbi.nlm.nih.gov/35658024/ (Accessed 2026-07-22).
4. BMJ global health (2024). Representation of racialised and ethnically diverse populations in multicentre randomised controlled trials of GLP-1 medicines for obesity: a systematic review and meta-analysis of gaps. PubMed PMID 39608857. https://pubmed.ncbi.nlm.nih.gov/39608857/ (Accessed 2026-07-22).
5. Obesity (Silver Spring, Md.) (2024). Efficacy and safety of semaglutide 2.4 mg by race and ethnicity: A post hoc analysis of three randomized controlled trials. PubMed PMID 38932728. https://pubmed.ncbi.nlm.nih.gov/38932728/ (Accessed 2026-07-22).

---

*This article is general education and is not medical advice. It cannot tell you what is right for your body. Talk with a licensed clinician about your own situation.*

*Written and clinically reviewed by Dr. Linda Moleon, MD. Last reviewed 2026-07-22.*